In recent months, multiple law firms announced securities class action lawsuits against Lantheus Holdings, alleging the company made misleading statements about the pricing and competitive dynamics of its oncology imaging agent, Pylarify, after disappointing sales results and lower guidance. These legal actions highlight investor concerns around transparency and disclosure, focusing particular attention on the challenges facing Lantheus’s Pylarify franchise and the company's communication...

Lantheus Holdings (LNTH) has seen its stock movement catch attention lately, with shares fluctuating even as many healthcare names remain steady. Investors might be weighing the company’s recent performance and underlying fundamentals as they search for signs of a potential turnaround. See our latest analysis for Lantheus Holdings. Lantheus Holdings has seen a modest rebound in recent weeks, with a 1-month share price return of about 8%. The longer-term picture still reflects a 1-year total...

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.